3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
4
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
34
Neoplasm Metastasis
7
Neoplasms
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms, Male
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Metastatic Breast Cancer With Intracranial Metastases
1
Melanoma
1
Inflammatory Breast Neoplasms
1
Her2 Positive Metastatic Breast Cancer
1
Head and Neck Neoplasms
1
HER2 Positive Esophagogastric Cancer
1
GastroEsophageal Cancer
1
Esophageal Squamous Cell Carcinoma
1
Diarrhea
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal, Breast
1
Carcinoma
1
Breast Diseases
1
Brain Neoplasms
1
Interventions
Docetaxel
56
Prednisone
36
enzalutamide
25
Leuprolide
24
Magnetic Resonance Spectroscopy
19
Abiraterone Acetate
19
bicalutamide
17
Radiotherapy
15
Goserelin
15
abiraterone
12
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
olaparib
9
Androgen Antagonists
9
gallium 68 PSMA-11
8
cabazitaxel
8
Radiotherapy, Intensity-Modulated
8
Metformin
8
Ketoconazole
8
Gonadotropin-Releasing Hormone
8
Cyclophosphamide
8
apalutamide
7
Doxorubicin
7
luprolide acetate gel depot
6
cabozantinib
6
Radiosurgery
6
Estramustine
6
Dexamethasone
6
Calcitriol
6
Biopsy
6
pembrolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostatic Neoplasms
×
Lapatinib
×
Clear all
NCT00953576
2018-09-04
KHLAD
Dana-Farber Cancer Institute
Phase 1/2
Terminated
11 enrolled
9 charts